Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cordyceps sinensis mycelium is a product derived from the fermented mycelium of the fungus *Cordyceps sinensis*, used in traditional Chinese medicine. [1, 3] A specific preparation, known by the brand names Corbrin Capsule or Bailing Capsule, is approved as a drug in China and contains fermented *Cordyceps sinensis* powder (Cs-C-Q80). [1, 3, 7] It is studied for its immunomodulatory, anti-inflammatory, and antioxidant properties. [8, 13, 18] Clinical trials and studies are investigating its use for various conditions, including chronic kidney disease, respiratory diseases like chronic obstructive pulmonary disease (COPD), and as an immune system modulator. [3, 7, 12] The active constituents are believed to include cordycepin, polysaccharides, adenosine, and ergosterol. [1, 2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cordyceps sinensis mycelium.